Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation

被引：6

作者：

Bejanyan, Nelli ^{[1
]}

Zhang, Mei-Jie ^{[2
,3
]}

Wang, Hai-Lin ^{[3
]}

Lazaryan, Aleksandr ^{[1
]}

de Lima, Marcos ^{[4
]}

Marks, David I. ^{[5
]}

Sandmaier, Brenda M. ^{[6
,7
]}

Bachanova, Veronika ^{[1
]}

Rowe, Jacob ^{[8
]}

Tallman, Martin ^{[9
]}

Kebriaei, Partow ^{[10
]}

Kharfan-Dabaja, Mohamed ^{[11
]}

Gale, Robert Peter ^{[12
]}

Lazarus, Hillard M. ^{[13
]}

Ustun, Celalettin ^{[1
]}

Copelan, Edward ^{[14
]}

Hamilton, Betty Ky ^{[15
]}

Schiller, Gary ^{[16
]}

Hogan, William ^{[17
,18
]}

Hashmi, Shahrukh ^{[19
,20
]}

Seftel, Matthew ^{[21
]}

Kanakry, Christopher G. ^{[22
]}

Olsson, Richard F. ^{[23
,24
]}

Martino, Rodrigo ^{[25
]}

Saber, Wael ^{[3
]}

Khoury, H. Jean ^{[26
]}

Weisdorf, Daniel J. ^{[1
]}

机构：

[1] Univ Minnesota, Div Hematol Oncol & Transplantat, 420 Delaware St SE,Mayo Mail Code 480, Minneapolis, MN 55455 USA

[2] Med Coll Wisconsin, Inst Hlth & Soc, Div Biostat, Milwaukee, WI 53226 USA

[3] Med Coll Wisconsin, Dept Med, CIBMTR Ctr Int Blood & Marrrow Trasnsplantat, Milwaukee, WI 53226 USA

[4] Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA

[5] Univ Hosp Bristol NHS Trust, Adult Bone Marrow Transplant, Bristol, Avon, England

[6] Univ Washington, Div Med Oncol, Seattle, WA 98195 USA

[7] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA

[8] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[9] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10021 USA

[10] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Stem Cell Transplantat, Houston, TX 77030 USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL USA

[12] Imperial Coll London, Div Expt Med, Dept Med, Hematol Res Ctr, London, England

[13] Univ Hosp Cleveland Med Ctr, Seidman Canc Ctr, Cleveland, OH USA

[14] Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[15] Cleveland Clin, Taussig Canc Inst, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA

[16] Univ Calif Los Angeles, David Geffen Sch Med, Hematol Malignancy Stem Cell Transplant Program, Los Angeles, CA 90095 USA

[17] Mayo Clin Rochester, Dept Hematol, Rochester, MN USA

[18] Mayo Clin Rochester, Transplant Ctr, Rochester, MN USA

[19] Mayo Clin, Dept Internal Med, Rochester, MN USA

[20] King Faisal Specialist Hosp & Res Ctr, Ctr Oncol, Riyadh, Saudi Arabia

[21] CancerCare Manitoba, Dept Med Oncol & Hematol, Winnipeg, MB, Canada

[22] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[23] Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden

[24] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden

[25] Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain

[26] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA

来源：

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2018年 / 24卷 / 05期

关键词：

ALL; Consolidation chemotherapy; Myeloablative.conditioning; Allogeneic transplant; ACUTE LYMPHOBLASTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; STEM-CELL TRANSPLANTATION; 1ST COMPLETE REMISSION; BONE-MARROW-TRANSPLANTATION; TERM-FOLLOW-UP; GROUP-B; RETROSPECTIVE ANALYSIS; REDUCED-INTENSITY; LALA-94; TRIAL;

D O I：

10.1016/j.bbmt.2017.12.784

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received >2 (n = 109), 1 (n = 93), or 0 cycles (n = 322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk, 1.20, 95% confidence interval,.86 to 1.67; P=.28 for no consolidation; RR, 1.18, 95% confidence interval,.79 to 1.76; P=.41 for 1 cycle versus.>:2 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1. (C) 2017 American Society for Blood and Marrow Transplantation.

引用

页码：945 / 955

页数：11

共 41 条

[11] Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -: results of the prospective multicenter LALA-94 trial
Dombret, H
Gabert, J
Boiron, JM
Rigal-Huguet, F
Blaise, D
Thomas, X
Delannoy, A
Buzyn, A
Bilhou-Nabera, C
Cayuela, JM
Fenaux, P
Bourhis, JH
Fegueux, N
Charrin, C
Boucheix, C
Lhéritier, V
Espérou, H
MacIntyre, E
Vernant, JP
Fière, D
[J]. BLOOD, 2002, 100 (07) : 2357 - 2366
[12] EGUIGUREN JM, 1992, BLOOD, V79, P871
[13] Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia
Fathi, Amir T.
DeAngelo, Daniel J.
Stevenson, Kristen E.
Kolitz, Jonathan E.
Asch, Julie D.
Amrein, Philip C.
Attar, Eyal C.
Steensma, David P.
Wadleigh, Martha
Foster, Julia
Connolly, Christine
Galinsky, Ilene
Devoe, Craig E.
Stone, Richard M.
Neuberg, Donna S.
Ballen, Karen K.
[J]. CANCER, 2016, 122 (15) : 2379 - 2388
[14] CLINICAL MANIFESTATIONS OF GRAFT VERSUS HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL-A-MATCHED SIBLING DONORS
GLUCKSBERG, H
STORB, R
FEFER, A
BUCKNER, CD
NEIMAN, PE
CLIFT, RA
LERNER, KG
THOMAS, ED
[J]. TRANSPLANTATION, 1974, 18 (04) : 295 - 304
[15] In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Goldstone, Anthony H.
Richards, Susan M.
Lazarus, Hillard M.
Tallman, Martin S.
Buck, Georgina
Fielding, Adele K.
Burnett, Alan K.
Chopra, Raj
Wiernik, Peter H.
Foroni, Letizia
Paietta, Elisabeth
Litzow, Mark R.
Marks, David I.
Durrant, Jill
McMillan, Andrew
Franklin, Ian M.
Luger, Selina
Ciobanu, Niculae
Rowe, Jacob M.
[J]. BLOOD, 2008, 111 (04) : 1827 - 1833
[16] PROGNOSTIC FACTORS IN A MULTICENTER STUDY FOR TREATMENT OF ACUTE LYMPHOBLASTIC-LEUKEMIA IN ADULTS
HOELZER, D
THIEL, E
LOFFLER, H
BUCHNER, T
GANSER, A
HEIL, G
KOCH, P
FREUND, M
DIEDRICH, H
RUHL, H
MASCHMEYER, G
LIPP, T
NOWROUSIAN, MR
BURKERT, M
GERECKE, D
PRALLE, H
MULLER, U
LUNSCKEN, C
FULLE, H
HO, AD
KUCHLER, R
BUSCH, FW
SCHNEIDER, W
GORG, C
EMMERICH, B
BRAUMANN, D
VAUPEL, HA
VONPALESKE, A
BARTELS, H
NEISS, A
MESSERER, D
[J]. BLOOD, 1988, 71 (01) : 123 - 131
[17] Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study
Huguet, Francoise
Leguay, Thibaut
Raffoux, Emmanuel
Thomas, Xavier
Beldjord, Kheira
Delabesse, Eric
Chevallier, Patrice
Buzyn, Agnes
Delannoy, Andre
Chalandon, Yves
Vernant, Jean-Paul
Lafage-Pochitaloff, Marina
Chassevent, Agnes
Lheritier, Veronique
Macintyre, Elizabeth
Bene, Marie-Christine
Ifrah, Norbert
Dombret, Herve
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (06) : 911 - 918
[18] A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor
Kako, S.
Morita, S.
Sakamaki, H.
Ogawa, H.
Fukuda, T.
Takahashi, S.
Kanamori, H.
Onizuka, M.
Iwato, K.
Suzuki, R.
Atsuta, Y.
Kyo, T.
Sakura, T.
Jinnai, I.
Takeuchi, J.
Miyazaki, Y.
Miyawaki, S.
Ohnishi, K.
Naoe, T.
Kanda, Y.
[J]. LEUKEMIA, 2011, 25 (02) : 259 - 265
[19] Long-Term Follow-up of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact of Tyrosine Kinase Inhibitors on Treatment Outcomes
Kebriaei, Partow
Saliba, Rima
Rondon, Gabriela
Chiattone, Alexandre
Luthra, Rajyalakshmi
Anderlini, Paolo
Andersson, Borje
Shpall, Elizabeth
Popat, Uday
Jones, Roy
Worth, Laura
Ravandi, Farhad
Thomas, Deborah
O'Brien, Susan
Kantarjian, Hagop
de Lima, Marcos
Giralt, Sergio
Champlin, Richard
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (04) : 584 - 592
[20] Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia
Knechtli, CJC
Goulden, NJ
Hancock, JP
Grandage, VLG
Harris, EL
Garland, RJ
Jones, CG
Rowbottom, AW
Hunt, LP
Green, AF
Clarke, E
Lankester, AW
Cornish, JM
Pamphilon, DH
Steward, CG
Oakhill, A
[J]. BLOOD, 1998, 92 (11) : 4072 - 4079

← 1 2 3 4 5 →